FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
FDA Advisory Committee Votes: neffy Data Support a Favorable Benefit-Risk Assessment in Adults and in Children <18 years of age and ≥30 kg If Approved, neffy Will Become the First Needle-Free... | May 11, 2023
Source: marketscreener.com
